How to Choose the Best Probiotic Against Helicobacter pylori?

Helicobacter pylori: symptoms and usage profiles

H. pylori colonizes the gastric mucosa thanks to urease, which raises the local pH and protects the bacterium in an acidic environment. This biology conditions the design: gastro-resistance, adhesion to mucin and activity in microaerophilic conditions are key. The most common symptoms are:

Functional dyspepsia: epigastric pain or burning, early satiety, postprandial distension, frequent belching.
Gastritis: diffuse epigastric discomfort with intermittent nausea; sometimes halitosis linked to alteration of the gastric microenvironment.
Peptic ulcer: rhythmic pain with meals, nocturnal in duodenal cases; it may occur with loss of appetite and weight loss.
Associated manifestations: digestive intolerance to antibiotics during eradication therapies (diarrhea, soft stools, meteorism), occasional reflux and a feeling of a “sensitive stomach”.

To guide the formulation we work in three usage scenarios:

Adjunct to eradication therapy (PPI + antibiotics ± bismuth), where we seek to improve gastrointestinal tolerability and adherence by separating doses 2–3 h and using protected release.
Support in associated dyspepsia, prioritizing strains with mucin adhesion and epithelial barrier reinforcement.
Maintenance after eradication, with stable formulations that promote recovery of the gastric/duodenal ecosystem.

How to formulate a probiotic for Helicobacter pylori?

The most effective strains against helicobacter pylori are:

Limosilactobacillus reuteri: strains capable of producing antimicrobial compounds and with good mucin adhesion.
Lacticaseibacillus rhamnosus / Lacticaseibacillus casei: adhesion and local immune modulation.
Lactobacillus acidophilus / Ligilactobacillus gasseri: acid balance and epithelial barrier.
Saccharomyces boulardii: non-bacterial yeast useful for GI tolerability in co-treatments.

It is the strain with the strongest evidence for reducing diarrhea associated with antibiotic use and improving tolerability and adherence to treatment. Probiotics can be a useful complement during certain treatments, but they do not in any case replace antibiotic therapy, which remains essential to eradicate the infection. Their function is to support the therapeutic process by helping to:

Reduce adverse effects
Modulate gastric inflammation
Decrease bacterial load
Improve treatment adherence

Relevant mechanisms of action

We recommend combining complementary mechanisms:

Adhesion competition
Local microbiostasis
Epithelial barrier reinforcement
Immune modulation
Mitigation of adverse effects

Formulation matrix

Gastro-resistance and release through microencapsulation: alginate, pectin, alginate-chitosan complexes, modified starches.
Compatibility with co-treatments: screening of surfactants and salts to avoid viability losses.
Quality and stability control: CFU at end of shelf life, sorption isotherms, accelerated and real-time studies; compression and filling tests, and enteric disintegration to ensure consistent dosing.

Design and evaluation of probiotics for Helicobacter pylori

To obtain a highly effective probiotic, we must combine a rational design of strains and matrix with a scalable preclinical evaluation. Our approach integrates bioprocesses, advanced microencapsulation and proprietary in vitro technologies, together with regulatory support, to reduce risks and accelerate market entry.

1) Discovery and characterization of strains

We start from our own collection. We carry out functional screening and discard profiles with risks of transmissible AMR.

2) Process design and biotechnological scaling

We optimize the fermentation process to maximize viability and robustness; we define stabilization strategies compatible with the target format. This stage is coordinated with formulation requirements.

3) Matrix and delivery technology

We select and adjust customized microencapsulation processes or gastro-resistant capsules to ensure survival through gastric transit and release in the target window.

4) In vitro preclinical evaluation

Through our dynamic in vitro digester (DigestSim ®) we reproduce pH gradients, enzymes and realistic residence times to measure survival, release profile of microencapsulated systems and post-digestion functional activity against H. pylori.

5) Gastric and intestinal cellular models

We quantify TEER, mucins, IL-8 and other biomarkers to demonstrate barrier reinforcement and modulation of the inflammatory response.

6) Stability and regulatory compliance

We validate shelf life under accelerated and real-time conditions and ensure compliance with labelling/claims with specialized legal advice.

Responsible	AINIA
Address	Calle Benjamín Franklin, 5 a 11, CP 46980 Paterna (Valencia)
Purpose	To attend to, register and contact you to resolve the request you make to us through this contact form
Legitimation	Your data will be processed only with your consent, by checking the box shown on this form
Recipients	Your data will not be transferred to third parties.
Rights	You have the right to request access to, correct or delete your data. You can also request that we limit its processing, oppose it and request the portability of your data by contacting our postal address or [email protected]
More info	You can find more information in our Privacy Policy
DPO	If you have any questions about how we will treat your data or would like to make any suggestions or complaints, please contact the Data Protection Officer at [email protected] or at the Data subject support form

How to Choose the Best Probiotic Against Helicobacter pylori?

Helicobacter pylori: symptoms and usage profiles